Immucell Corp (ICCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,809 | 1,949 | 1,447 | -2,157 | -2,671 |
| Depreciation Amortization | 2,075 | 1,366 | 687 | 2,730 | 2,045 |
| Accounts receivable | 1,216 | 1,392 | 425 | -1,586 | -123 |
| Accounts payable and accrued liabilities | -173 | -306 | -531 | 363 | 387 |
| Other Working Capital | -1,838 | -179 | -579 | -407 | 828 |
| Other Operating Activity | -1,097 | -1,047 | 126 | 1,414 | -106 |
| Operating Cash Flow | $1,993 | $3,175 | $1,574 | $358 | $361 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,047 | -455 | -329 | -461 | -265 |
| Investing Cash Flow | $-1,047 | $-455 | $-329 | $-461 | $-265 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 801 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 349 | 349 | 19 | 4,648 | 4,109 |
| Other Financing Activity | -1,968 | -829 | -423 | -1,765 | -1,375 |
| Financing Cash Flow | $-818 | $-480 | $-404 | $2,883 | $2,734 |
| Beginning Cash Position | 3,758 | 3,758 | 3,758 | 979 | 979 |
| End Cash Position | 3,886 | 5,999 | 4,599 | 3,758 | 3,809 |
| Net Cash Flow | $128 | $2,240 | $841 | $2,780 | $2,830 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,993 | 3,175 | 1,574 | 358 | 361 |
| Capital Expenditure | -1,078 | -484 | -329 | -466 | -270 |
| Free Cash Flow | 915 | 2,691 | 1,245 | -108 | 92 |